Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
28/06/2024 | 14:17 | GlobeNewswire Inc. | Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines | NASDAQ:ARDX | Ardelyx Inc |
18/06/2024 | 00:53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARDX | Ardelyx Inc |
17/06/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARDX | Ardelyx Inc |
13/06/2024 | 22:12 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ARDX | Ardelyx Inc |
04/06/2024 | 14:57 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:ARDX | Ardelyx Inc |
30/05/2024 | 22:02 | GlobeNewswire Inc. | Ardelyx, Inc. Reports Employment Inducement Grants | NASDAQ:ARDX | Ardelyx Inc |
22/05/2024 | 14:02 | GlobeNewswire Inc. | Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference | NASDAQ:ARDX | Ardelyx Inc |
21/05/2024 | 14:02 | GlobeNewswire Inc. | Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults | NASDAQ:ARDX | Ardelyx Inc |
16/05/2024 | 14:01 | GlobeNewswire Inc. | Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) | NASDAQ:ARDX | Ardelyx Inc |
07/05/2024 | 14:01 | GlobeNewswire Inc. | Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference | NASDAQ:ARDX | Ardelyx Inc |
02/05/2024 | 22:02 | GlobeNewswire Inc. | Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:ARDX | Ardelyx Inc |
01/05/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings | NASDAQ:ARDX | Ardelyx Inc |
18/04/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 | NASDAQ:ARDX | Ardelyx Inc |
25/03/2024 | 13:00 | GlobeNewswire Inc. | Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy | NASDAQ:ARDX | Ardelyx Inc |
27/02/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Participate at the Cowen 44th Annual Health Care Conference | NASDAQ:ARDX | Ardelyx Inc |
22/02/2024 | 22:40 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ARDX | Ardelyx Inc |
22/02/2024 | 22:01 | GlobeNewswire Inc. | Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:ARDX | Ardelyx Inc |
22/02/2024 | 12:05 | IH Market News | U.S. Futures Surge on Nvidia’s Stellar Performance, Global Markets Respond Positively | NASDAQ:ARDX | Ardelyx Inc |
01/02/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 | NASDAQ:ARDX | Ardelyx Inc |
08/01/2024 | 14:00 | GlobeNewswire Inc. | Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities | NASDAQ:ARDX | Ardelyx Inc |
03/01/2024 | 14:03 | GlobeNewswire Inc. | Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 | NASDAQ:ARDX | Ardelyx Inc |
21/11/2023 | 14:01 | GlobeNewswire Inc. | Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference | NASDAQ:ARDX | Ardelyx Inc |
15/11/2023 | 22:02 | GlobeNewswire Inc. | XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia | NASDAQ:ARDX | Ardelyx Inc |
13/11/2023 | 22:02 | GlobeNewswire Inc. | Ardelyx Announces Departure of Board Member | NASDAQ:ARDX | Ardelyx Inc |
10/11/2023 | 14:05 | GlobeNewswire Inc. | Ardelyx to Participate at the Jefferies London Healthcare Conference | NASDAQ:ARDX | Ardelyx Inc |
06/11/2023 | 14:00 | GlobeNewswire Inc. | Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States | NASDAQ:ARDX | Ardelyx Inc |
03/11/2023 | 13:00 | GlobeNewswire Inc. | Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 | NASDAQ:ARDX | Ardelyx Inc |
31/10/2023 | 12:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARDX | Ardelyx Inc |
31/10/2023 | 12:00 | GlobeNewswire Inc. | Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance | NASDAQ:ARDX | Ardelyx Inc |
23/10/2023 | 14:07 | GlobeNewswire Inc. | Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023 | NASDAQ:ARDX | Ardelyx Inc |